No profile data available.
Gossamer Bio, Inc. (GOSS) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in San Diego, United States, with about 161 full-time employees.
It reported revenue of $48.47 million for fiscal year 2025, down 57.7% from fiscal year 2024, and net income of -$170.37 million. Its market capitalization was $56.94 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
Gossamer Bio reported $48.47 million in revenue for fiscal year 2025, down 57.7% from $114.70 million in fiscal year 2024.
$56.94 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include Tectonic Therapeutic, Inc. (TECX), DiaMedica Therapeutics Inc. (DMAC), Tenax Therapeutics, Inc. (TENX), Grace Therapeutics, Inc. (GRCE).